- Kenvue Inc.
Kenvue Inc.
Website
Offer Price
Offer Size
3-Year Outlook
Volatility
1st Day Turnover
$22.00
172,800,000
Positive
High
44.56%
Offering Team
Deal Managers
- Goldman Sachs
- J P Morgan Chase
- Bank of America Merrill Lynch
Lawyers
- Cravath, Swaine & Moore LLP
Auditors
- PricewaterhouseCoopers LLP
Pre-IPO Investors
Investors
- Google Ventures
- Intel Ventures
- Patricoff Ventures
- Kleiner Perkins
Pre-IPO Holdings(%)
- 30
- 20
- 05
- 18
Deal Highlights
We are the world’s largest pure-play consumer health company by revenue with $15.1 billion in net sales in 2021. We combine the power of science with meaningful human insights and digital-first capabilities, which we believe empowers approximately 1.2 billion people to live healthier lives every day. Our differentiated portfolio of iconic brands—including Tylenol, Neutrogena, Listerine, Johnson’s, Band-Aid, Aveeno, Zyrtec and Nicorette—is built for moments that unique More
Deal Tracker
Investors
Filing
03 May, 2023Offer
04 May, 2023Look Ahead
Lock Up Expiry
04 Nov, 2023Earning
Nov 1, 2018IPO Terms
Offer Price | $22.00 |
Offer Size | 172M |